{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:58:20Z","timestamp":1774501100456,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s42000-021-00307-0","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T07:02:43Z","timestamp":1625727763000},"page":"491-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-7896","authenticated-orcid":false,"given":"Soner","family":"Cander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozen","family":"Oz Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eda","family":"Eylemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Gullulu Boz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahattin","family":"Hakyemez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selcuk","family":"Yilmazlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"9","key":"307_CR1","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","volume":"95","author":"A Raappana","year":"2010","unstructured":"Raappana A, Koivukangas J, Ebeling T, Piril\u00e4 T (2010) Incidence of pituitary adenomas in Northern Finland in 1992\u20132007. J Clin Endocrinol Metab 95(9):4268\u20134275. https:\/\/doi.org\/10.1210\/jc.2010-0537","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"307_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2011","unstructured":"Colao A, Savastano S (2011) Medical treatment of prolactinomas. Nat Rev Endocrinol 7(5):267\u2013278. https:\/\/doi.org\/10.1038\/nrendo.2011.37","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"307_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000495184","volume":"109","author":"I Shimon","year":"2019","unstructured":"Shimon I (2019) Giant prolactinomas. Neuroendocrinology 109(1):51\u201356. https:\/\/doi.org\/10.1159\/000495184","journal-title":"Neuroendocrinology"},{"issue":"3","key":"307_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","volume":"52","author":"E Espinosa","year":"2016","unstructured":"Espinosa E, Sosa E, Mendoza V, Ram\u00edrez C, Melgar V, Mercado M (2016) Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine 52(3):652\u2013659. https:\/\/doi.org\/10.1007\/s12020-015-0791-7","journal-title":"Endocrine"},{"issue":"4","key":"307_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"19","author":"I Shimon","year":"2016","unstructured":"Shimon I, Sosa E, Mendoza V et al (2016) Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 19(4):429\u2013436. https:\/\/doi.org\/10.1007\/s11102-016-0723-4","journal-title":"Pituitary"},{"key":"307_CR6","doi-asserted-by":"publisher","unstructured":"Delgrange E, Raverot G, Bex M, et al. (2013) Giant prolactinomas in women. Eur J Endocrinol 22(170 (1)):31\u20138. https:\/\/doi.org\/10.1530\/EJE-13-0503","DOI":"10.1530\/EJE-13-0503"},{"issue":"4","key":"307_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.12242","volume":"79","author":"AB Moraes","year":"2013","unstructured":"Moraes AB, Silva CM, Vieira Neto L, Gadelha MR (2013) Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf) 79(4):447\u2013456. https:\/\/doi.org\/10.1111\/cen.12242","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"307_CR8","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170(6):R213\u2013R227. https:\/\/doi.org\/10.1530\/EJE-14-0013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"307_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR10","unstructured":"Rem\u00f3n-Ruiz P, Venegas-Moreno E, Dios Fuentes E, et al. (2020) Our experience in prolactinomas larger than 60mm. Endocrinol Diabetes Nutr 26:S2530\u20130164(20)30152-X"},{"issue":"1","key":"307_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.endinu.2020.03.012","volume":"68","author":"R-R English","year":"2021","unstructured":"English R-R, Venegas-Moreno E, Dios Fuentes E et al (2021) Our experience in prolactinomas larger than 60mm. Endocrinol Diabetes Nutr 68(1):3\u201310. https:\/\/doi.org\/10.1016\/j.endinu.2020.03.012","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"4","key":"307_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4158\/EP-2018-0392","volume":"25","author":"O Hamidi","year":"2019","unstructured":"Hamidi O, Van Gompel J, Gruber L et al (2019) Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract 25(4):340\u2013352. https:\/\/doi.org\/10.4158\/EP-2018-0392","journal-title":"Endocr Pract"},{"issue":"4","key":"307_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/br.2014.281","volume":"2","author":"S Cander","year":"2014","unstructured":"Cander S, Karkucak M, Gul OO et al (2014) Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study. Biomed Rep 2(4):589\u2013595. https:\/\/doi.org\/10.3892\/br.2014.281","journal-title":"Biomed Rep"},{"issue":"5","key":"307_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1046\/j.1365-2265.2003.01770.x","volume":"58","author":"SM Corsello","year":"2003","unstructured":"Corsello SM, Ubertini G, Altomare M et al (2003) Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 58(5):662\u2013670. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01770.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"307_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.gene.2012.07.056","volume":"509","author":"S Cander","year":"2012","unstructured":"Cander S, Ert\u00fcrk E, Karkucak M et al (2012) Effect of cyclin [corrected] D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma. Gene 509(1):158\u2013163. https:\/\/doi.org\/10.1016\/j.gene.2012.07.056","journal-title":"Gene"},{"key":"307_CR16","doi-asserted-by":"publisher","unstructured":"Hwang J, Seol HJ, Nam DH, Lee JI, Lee MH, Kong DS (2016) Therapeutic strategy for cavernous sinus-invading non-functioning pituitary adenomas based on the modified knosp grading system.\u00a0Brain Tumor Res Treat 4(2):63\u20139. https:\/\/doi.org\/10.14791\/btrt.2016.4.2.63.","DOI":"10.14791\/btrt.2016.4.2.63"},{"issue":"2","key":"307_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-19-0753","volume":"182","author":"D Kim","year":"2020","unstructured":"Kim D, Ku CR, Kim K, Jung H, Lee EJ (2020) Prolactin \u22641 ng\/mL predicts macroprolactinoma reduction after cabergoline therapy. Eur J Endocrinol 182(2):177\u2013183. https:\/\/doi.org\/10.1530\/EJE-19-0753","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"307_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5603\/EP.2014.0029","volume":"65","author":"S Cander","year":"2014","unstructured":"Cander S, G\u00fcl \u00d6\u00d6, Ert\u00fcrk E, Tuncel E, Ersoy C (2014) Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not. Endokrynol Pol 65(3):210\u2013216. https:\/\/doi.org\/10.5603\/EP.2014.0029","journal-title":"Endokrynol Pol"},{"issue":"1","key":"307_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","volume":"23","author":"H Duskin-Bitan","year":"2020","unstructured":"Duskin-Bitan H, Shimon I (2020) Prolactinomas in males: any differences? Pituitary 23(1):52\u201357. https:\/\/doi.org\/10.1007\/s11102-019-01009-y","journal-title":"Pituitary"},{"key":"307_CR20","doi-asserted-by":"publisher","unstructured":"Moisi M, Cruz AS, Benkers T, et al (2016) Treatment of aggressive prolactin-secreting pituitary adenomas with adjuvant temozolomide chemotherapy: a review. Cureus 8(6):e658. Published. https:\/\/doi.org\/10.7759\/cureus.658.","DOI":"10.7759\/cureus.658"},{"issue":"45","key":"307_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013198","volume":"97","author":"YL Han","year":"2018","unstructured":"Han YL, Chen DM, Zhang C, Pan M, Yang XP, Wu YG (2018) Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Med (Baltim) 97(45):e13198. https:\/\/doi.org\/10.1097\/MD.0000000000013198","journal-title":"Med (Baltim)"},{"issue":"2","key":"307_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12020-018-1702-5","volume":"62","author":"HY Huang","year":"2018","unstructured":"Huang HY, Zhai W, Tang H, Hui GZ, Wu ZB (2018) Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine 62(2):464\u2013469. https:\/\/doi.org\/10.1007\/s12020-018-1702-5","journal-title":"Endocrine"},{"key":"307_CR23","doi-asserted-by":"publisher","first-page":"117955142092618","DOI":"10.1177\/1179551420926181","volume":"13","author":"MH Almalki","year":"2020","unstructured":"Almalki MH, Aljohani N, Alzahrani S et al (2020) Clinical features, therapeutic trends, and outcome of giant prolactinomas: A single-center experience over a 12-year period. Clin Med Insights Endocrinol Diabetes 13:1179551420926181. https:\/\/doi.org\/10.1177\/1179551420926181","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"5","key":"307_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/a-0597-8877","volume":"127","author":"L Lv","year":"2019","unstructured":"Lv L, Hu Y, Yin S et al (2019) Giant prolactinomas: outcomes of multimodal treatments for 42 cases with long-term follow-up. Exp Clin Endocrinol Diabetes 127(5):295\u2013302. https:\/\/doi.org\/10.1055\/a-0597-8877","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"307_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.wneu.2020.08.129","volume":"144","author":"D Abe","year":"2020","unstructured":"Abe D, Ogiwara T, Nakamura T et al (2020) Treatment strategy for giant invasive macroprolactinoma with spontaneous cerebrospinal fluid rhinorrhea: A case report and literature review. World Neurosurg 144:19\u201323. https:\/\/doi.org\/10.1016\/j.wneu.2020.08.129","journal-title":"World Neurosurg"},{"issue":"5","key":"307_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","volume":"158","author":"S Akin","year":"2016","unstructured":"Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M (2016) Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir (Wien) 158(5):933\u2013942. https:\/\/doi.org\/10.1007\/s00701-016-2762-z","journal-title":"Acta Neurochir (Wien)"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-021-00307-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T02:10:48Z","timestamp":1628734248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-021-00307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1007\/s42000-021-00307-0","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with guidelines in the Declaration of Helsinki and approved by the Institutional Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}